Anhui zhifei vaccine was inoculated in three doses with an interval of 28 days. According to the increasing vaccination rate, the demand for vaccines is increasing. According to the relevant person in charge of Anhui Zhifeilong Kyle Biopharmaceutical Co., Ltd., at present, the company has built a production line with an annual output of 300 million doses of COVID-19 vaccine, which is equivalent to meeting the vaccination of 654.38+0 billion people. In addition, in order to expand the vaccine production capacity, the company will add six production lines, which are scheduled to be completed before the end of September, and the production capacity will increase by 600 million doses after production.
Study on the Effectiveness of zhifei Vaccine;
The target of recombinant COVID-19 vaccine is 18 years old and above, and there is no contraindication.
The vaccination procedure is 3 doses throughout the whole course. The interval between two adjacent doses is recommended to be ≥4 weeks. The second dose should be completed within 8 weeks after 1 dose, and the third dose should be completed within 6 months after 1 dose. Intramuscular injection of deltoid muscle of upper arm.
The safety of recombinant subunit vaccine is good, most subjects have no adverse reactions, and a few subjects may have pain, redness or induration at the inoculation site, which can basically heal themselves within 1-3 days.
In terms of effectiveness, the second-phase clinical trial of three-needle recombinant protein subunit COVID-19 vaccine in adults aged 65,438+08-59 showed that the positive conversion rate of neutralizing antibody of real virus reached 83% after two doses of vaccine inoculation and 97% after three doses of vaccine inoculation, which was twice as high as that of serum neutralizing antibody of rehabilitation patients in COVID-19, and the positive conversion rate of RBD protein-bound antibody reached 99%.
Guangdong Provincial People's Government-COVID-19 Vaccine Three Needles Come to Guangdong! These people can be vaccinated.